Turoctocog alfa (Novo Nordisk) filed for Haemophilia in US and EU - 17-Oct-2012
Novo Nordisk announced the submission of the regulatory application for turoctocog alfa (NN7008) to the European Medicines Agency (EMA) and the FDA. Turoctocog alfa is a third-generation recombinant coagulation factor VIII intended for prevention and treatment of bleeding in people with haemophilia A.
The decision to apply for marketing authorisation for turoctocog alfa is based upon the results of the clinical trials GUARDIAN 1 and GUARDIAN 3, which were completed in 2011. More than 200 people with haemophilia A around the world were enrolled, making GUARDIAN the largest clinical pre-registration trial programme conducted in haemophilia A. The phase III trials included previously treated adults and children with severe haemophilia A and demonstrated efficacy in preventing and treating bleeds with no development of inhibitors.
Related News
CHMP recommends approval of Voncento (CSL Behring) for Haemophilia A/Von Willebrand disease
Phase III trial for N9-GP(Novo Nordisk) treatment for Haemophilia B
FDA accepts BLA from Biogen for Eloctate for treatment of Haemophilia A
Biogen IDEC files rFVIII Fc at FDA for treatment of Haemophilia A
FDA expands approval of Corifact (CSL Behring) to manage surgical bleeding in adult and pediatric patients with Factor XIII Deficiency
Successful studies for rFVIIIFc and rFIXFc (Biogen/Swedish Orphan) for Haemopilia
BAX 855 enters Phase II/III study for Haemophilia
Biogen Idec files rFIXFc at FDA for treatment of Haemophilia B
Related Haematology Information
Haematology Clinical Guidelines
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
AidsinfoBritish HIV Association guidelines for the treatment of TB/HIV coinfection 2011
British HIV AssociationHaematology Clinical Trials
Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (DASAPOST)
Clinicaltrials.gov 27 February 2013A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
Clinical Trials Register.eu 05 February 2013Haematology Medical Journal Abstracts
Low-fat diet with omega-3 fatty acids increases plasma insulin–like growth factor concentration in healthy postmenopausal women
Nutrition Research 03 June 2013ProSeal laryngeal mask airway and endotracheal tube in elderly hypertensive patients undergoing routine surgical procedures: A comparison of hemodynamic parameters
Journal of Clinical Gerontology and Geriatrics 13 May 2013Haematology Medical Apps
The Oncologist
Free
ACP PIER Database - Hematology
£37.29
Related Haematology Drugs
- RIENSO 30 MG/ML SOLUTION FOR INJECTION
- MENADIOL DIPHOSPHATE TABLETS 10MG
- TREDAPTIVE 1000 MG/20 MG MODIFIED RELEASE TABLETS
- FEOSPAN SPANSULE CAPSULES
- FENOFIBRATE 267MG CAPSULES
- FLUVASTATIN 20MG CAPSULES
- FOLIC ACID 2.5MG/5ML ORAL SOLUTION
- FANHDI 25 I.U./ML, 50 I.U./ML AND 100 I.U./ML
- ALPHANINE
- OCTANATE 50IU/ML
- FERRIPROX 500 MG FILM-COATED TABLETS
- FLUVASTATIN 40MG CAPSULES
- HAEMONINE 500 / HAEMONINE 1000
- HAEMOCTIN 250 / HAEMOCTIN 500
- EPREX 2000, 4000 AND 10000 IU/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
- FERRIPROX 100 MG/ML ORAL SOLUTION
- FERSADAY 100MG TABLETS
- HAEMOCTIN 250 / HAEMOCTIN 500
- GALFER CAPSULES
- ARANESP SURECLICK
- HUMAN ALBUMIN BIOTEST 20%
Advert for Healthcare Professionals only